Tsiouda, T.; Domvri, K.; Boutsikou, E.; Bikos, V.; Kyrka, K.; Papadaki, K.; Pezirkianidou, P.; Porpodis, K.; Cheva, A.
Prognostic Value of KRAS Mutations in Relation to PDL1 Expression and Immunotherapy Treatment in Adenocarcinoma and Squamous Cell Carcinoma Patients: A Greek Cohort Study. J. Pers. Med. 2024, 14, 457.
https://doi.org/10.3390/jpm14050457
AMA Style
Tsiouda T, Domvri K, Boutsikou E, Bikos V, Kyrka K, Papadaki K, Pezirkianidou P, Porpodis K, Cheva A.
Prognostic Value of KRAS Mutations in Relation to PDL1 Expression and Immunotherapy Treatment in Adenocarcinoma and Squamous Cell Carcinoma Patients: A Greek Cohort Study. Journal of Personalized Medicine. 2024; 14(5):457.
https://doi.org/10.3390/jpm14050457
Chicago/Turabian Style
Tsiouda, Theodora, Kalliopi Domvri, Efimia Boutsikou, Vasileios Bikos, Krystallia Kyrka, Konstantina Papadaki, Persefoni Pezirkianidou, Konstantinos Porpodis, and Angeliki Cheva.
2024. "Prognostic Value of KRAS Mutations in Relation to PDL1 Expression and Immunotherapy Treatment in Adenocarcinoma and Squamous Cell Carcinoma Patients: A Greek Cohort Study" Journal of Personalized Medicine 14, no. 5: 457.
https://doi.org/10.3390/jpm14050457
APA Style
Tsiouda, T., Domvri, K., Boutsikou, E., Bikos, V., Kyrka, K., Papadaki, K., Pezirkianidou, P., Porpodis, K., & Cheva, A.
(2024). Prognostic Value of KRAS Mutations in Relation to PDL1 Expression and Immunotherapy Treatment in Adenocarcinoma and Squamous Cell Carcinoma Patients: A Greek Cohort Study. Journal of Personalized Medicine, 14(5), 457.
https://doi.org/10.3390/jpm14050457